Nixon D W, Murphy G F, Sewell C W, Kutner M, Lynn M J
Cancer. 1979 Sep;44(3):1045-9. doi: 10.1002/1097-0142(197909)44:3<1045::aid-cncr2820440336>3.0.co;2-c.
Survival and histologic subtype were compared in 61 patients with small cell anaplastic lung cancer. Patients with lymphocyte-like (oat cell) and fusiform histologies treated with chemotherapy had longer median survivals than the polygonal and other varieties on the same treatment. Likewise, when detectable disease was confined to the chest and supraclavicular nodes, the patients with lymphocyte-like and fusiform types lived longer. The improved survival in the lymphocyte-like and fusiform categories accounted for most of our improved overall median survival rates with the COPP regimen in small cell lung cancer. Survival in the polygonal and other types was not appreciably different from that seen in non-small cell lung cancer (squamous and adenocarcinoma). It may be possible to refine treatment plans on the basis of cell type so as to further increase survival in small cell anaplastic lung carcinoma.
对61例小细胞间变性肺癌患者的生存率和组织学亚型进行了比较。接受化疗的淋巴细胞样（燕麦细胞）和梭形组织学类型的患者，其中位生存期比接受相同治疗的多边形及其他类型患者更长。同样，当可检测到的疾病局限于胸部和锁骨上淋巴结时，淋巴细胞样和梭形类型的患者存活时间更长。淋巴细胞样和梭形类型患者生存率的提高，是我们采用COPP方案治疗小细胞肺癌时总体中位生存率提高的主要原因。多边形及其他类型患者的生存率与非小细胞肺癌（鳞状细胞癌和腺癌）患者的生存率无明显差异。或许可以根据细胞类型优化治疗方案，以进一步提高小细胞间变性肺癌患者的生存率。
